COVID-19 and Diarylamidines: The Parasitic Connection
J Hulme - International Journal of Molecular Sciences, 2023 - mdpi.com
As emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
(Omicron) continue to outpace and negate combinatorial vaccines and monoclonal antibody …
(Omicron) continue to outpace and negate combinatorial vaccines and monoclonal antibody …
A drug repurposing approach for antimalarials interfering with SARS-CoV-2 spike protein receptor binding domain (RBD) and human angiotensin-converting enzyme …
Host cell invasion by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
mediated by the interaction of the viral spike protein (S) with human angiotensin-converting …
mediated by the interaction of the viral spike protein (S) with human angiotensin-converting …
Candidate drugs against SARS-CoV-2 and COVID-19
DL McKee, A Sternberg, U Stange, S Laufer… - Pharmacological …, 2020 - Elsevier
Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global
health for the future. Because a vaccine against the virus will not be available in the near …
health for the future. Because a vaccine against the virus will not be available in the near …
Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
W Fu, Y Chen, K Wang, A Hettinghouse, W Hu… - Protein & …, 2021 - academic.oup.com
The ongoing coronavirus disease 2019 (COVID-19) global pandemic is caused by a novel
coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which …
coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which …
Tackling SARS-CoV-2: proposed targets and repurposed drugs
The SARS-CoV-2 pandemic, declared as a global health emergency by the WHO in
February 2020, has currently infected more than 6 million people with fatalities near 371,000 …
February 2020, has currently infected more than 6 million people with fatalities near 371,000 …
[HTML][HTML] Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome
Abstract The coronavirus disease 2019 (COVID-19) pandemic has heavily challenged the
global healthcare system. Despite the vaccination programs, the new virus variants are …
global healthcare system. Despite the vaccination programs, the new virus variants are …
Small-molecule metabolites in SARS-CoV-2 treatment: a comprehensive review
R Alipoor, R Ranjbar - Biological Chemistry, 2023 - degruyter.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has quickly spread all
over the world. In this respect, traditional medicinal chemistry, repurposing, and …
over the world. In this respect, traditional medicinal chemistry, repurposing, and …
Insights into SARS-CoV-2: Medicinal chemistry approaches to combat its structural and functional biology
LS Zhuo, MS Wang, JF Yang, HC Xu, W Huang… - Topics in Current …, 2021 - Springer
Coronavirus disease 2019, caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is still a pandemic around the world. Currently, specific antiviral drugs to …
(SARS-CoV-2), is still a pandemic around the world. Currently, specific antiviral drugs to …
Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection
The urgency to find complementary therapies to current SARS-CoV-2 vaccines, whose
effectiveness is preserved over time and not compromised by the emergence of new and …
effectiveness is preserved over time and not compromised by the emergence of new and …
Current potential therapeutic approaches against SARS-CoV-2: a review
The ongoing SARS-CoV-2 pandemic is a serious threat to public health worldwide and, to
date, no effective treatment is available. Thus, we herein review the pharmaceutical …
date, no effective treatment is available. Thus, we herein review the pharmaceutical …